Assam makes strides in reducing Maternal Mortality, Infant Mortality and Under 5 Mortality ratios
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Tired of too many ads?
Remove Ads
Guwahati: Assam has made promising strides towards reducing the Maternal Mortality Ratio (MMR), Infant Mortality Rate (IMR) and the Under 5 Mortality Rate.Assam Chief Minister Himanta Biswa Sarma said this on Thursday while adding that while the recent reports of Sample Registration System (SRS) published by the Office of the Registrar General of India the MMR of Assam has come down to 125.He said that historically, Assam recorded the highest Maternal Mortality Ratio (MMR) in the country till the last SRS report of 2018-20. In 2001-03, the MMR in Assam was 490 per 1 lakh live births. At that time, the national MMR was 301.'The maternal health conditions were poor and the health infrastructure in the state was unable to provide necessary support to our mothers. In the last two decades, tremendous efforts have been undertaken, especially in the last 10 years, for which, significant improvement has been observed in reduction of maternal mortality,' the Chief Minister said adding that with the wholehearted efforts of Government of Assam in the last 20 years, the MMR has improved to 125 in 2020-22 from 490 in 2001-03.He said that the Special Bulletin on Maternal Mortality in India 2020-22 was released in the month of June 2025. 'As per SRS 2020-22, MMR of Assam has come down to 125 with a further 42 points (25.1%) drop in MMR compared to 2019-21. This shows 70 points (36%) drop in MMR in just 2 years. No other States in the Country have shown such decline,' he said, adding that Assam's MMR is now better than Madhya Pradesh (159), Chhattisgarh (141), Uttar Pradesh (141) and Odisha (136) as per SRS 2020-22.'It is a great achievement for the State of Assam to bring such a great reduction of MMR even during the period of COVID pandemic,' he said.The Chief Minister further added that it is not just MMR, but Infant Mortality rate also has improved tremendously. 'The IMR in 2005 in Assam was 68, way above the national IMR of 58, being one of the last states in the country. The Infant Mortality Rate (IMR) of Assam improved to 36 as per SRS (2020). It has come down to 34 as per SRS (2021) and further down to 32 as per SRS (2022),' he said adding that in terms of IMR, Assam's performance is at par with Orissa (32) and better than Uttar Pradesh (38), Chattisgarh (38) and Madhya Pradesh (40).'From 68 in 2005, we have improved to 32 by 2020-22, almost reducing IMR to 1/3rd,'he said, adding that the Under 5 Mortality Rate (U5MR) was as high as 88 per 1000 live births in 2008. This has also come down from 40 (SRS 2020) to 37 (SRS 2021) and further down to 35 (SRS 2022), almost reducing to 1/3rd,' Sarma said.'Similarly, our neonatal mortality rate also has improved from 33 per 1000 live births in 2005 to 22 in 2020-22,' he said adding that improvement in health infrastructure, improvement in health Human Resources (HR), Motivated and incentivised ASHA(s) and grassroots workers, improved health service delivery and the social support programmes contributed towards this achievement.Sarma stated that nearly 40,000 youths would be provided government jobs in a single recruitment drive scheduled for 10 October.Notably, appointment letters were distributed to 443 Veterinary Field Assistants in the Animal Husbandry & Veterinary Department, 12 Tourism Development Officers in the Tourism Department, and 23 DIET Lecturers and 3 SCERT Assistant Directors in the rank of Assistant Professors under the Education Department. With the inclusion of these 481 appointments, the total number of government jobs secured under the present administration now stands at 1,20,840.Sarma expressed confidence that the State Government is well on course to reach a total of 1.60 lakh appointments by 10 October. He emphasised that the transparent nature of this recruitment process has not only upheld merit, but also played a vital role in fostering a more robust educational ecosystem across the state.Turning his attention to the animal husbandry sector, the Chief Minister underscored its growing importance in the vision of a self-reliant Assam. He noted that, while this sector has increasingly become a pillar of the rural economy, Assam still lags behind other states in fully realising its potential. To address this, he stated that the government has partnered with the National Dairy Development Board to establish the North East Dairy and Foods Limited – an initiative aimed at producing, processing, and distributing 10 lakh litres of milk daily. He highlighted a series of infrastructural developments already underway to support this goal, including the setup of milk processing centres with one lakh litre capacities in Dhemaji, Jorhat, Dibrugarh, and Cachar, a 25,000 litre unit in Bajali, and a three lakh litre facility in Guwahati. He further mentioned that a new 1 lakh litre milk processing unit would also be established in Rani, near Guwahati by AMUL. These efforts, he affirmed, would serve as an incentive for farmers across Assam to expand production.Sarma stated that the state government would provide a subsidy of Rs. 5 per litre for milk brought in for processing. He added that the College of Veterinary Science, in collaboration with the National Dairy Development Board, is working to develop a new breed by crossbreeding Assam's indigenous Lakhimi cows with Gujarat's high-yielding Gir breed. Additionally, he shared that efforts are also underway to improve yield through artificial insemination. With these measures, he affirmed, the government aims to scale Assam's daily milk production to 15 lakh litres by 2030.Alongside livestock development, the Chief Minister emphasised the state's renewed focus on poultry and duck farming, noting that 90% of Assam's daily egg demand is currently met through imports. He observed that if merely 1,000 entrepreneurs' step forward, the state could achieve a daily production of one crore eggs within three years. Despite the Northeast hosting the country's largest pork market, he lamented the region's insufficient local production and stressed the government's commitment to addressing this gap. He also highlighted a national campaign to promote biogas and bio-CNG production, adding that efforts are underway to enable dairy enterprises to generate these from cattle dung - an initiative poised to offer farmers a valuable supplementary income stream.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
7 hours ago
- New Indian Express
Detaining student despite valid health grounds not right: Telangana HC
HYDERABAD: Justice K Sarath of the Telangana High Court has set aside a circular issued by Geethanjali College of Engineering and Technology, Keesara, dated June 12, 2025, detaining Kondaparthi Manvitha, a B Tech (CSE) student, from appearing in the III year II semester exams. The court directed the college authorities to publish her examination results and permit her to complete the course without further hindrance, considering her case on medical, merit, and humanitarian grounds. Manvitha had undergone surgeries for a severe lung condition in February and March 2025, leading to her absence from classes. She resumed attendance in April and paid the exam fee on May 23. However, the college detained her citing only 49.33% attendance, below the mandatory 65% required under Regulation 6 of the college's AR-22 academic rules. Justice Sarath, however, held that while regulations are essential, educational institutions must also consider merit and medical circumstances. Noting the petitioner's clean academic record, the court emphasised that education policies must balance rule enforcement with empathy.
Time of India
4 days ago
- Time of India
MP has highest infant mortality rate in India, govt admits in assembly
Bhopal: Madhya Pradesh has the highest infant mortality rate in the country, with 40 out of every 1,000 newborns dying in the state, the govt informed the assembly on Wednesday. The disclosure came in a written reply by Deputy CM and health minister Rajendra Shukla to a question raised by Congress MLA Jhuma Solanki. Citing the latest Sample Registration System (SRS) 2022 data, Shukla said the state's infant mortality rate (IMR) was not only higher than the national average but also the highest among all states. "Yes, the infant mortality rate in MP is higher compared to other states and the national average," he said. In her question, Solanki had sought comparative figures, reasons behind the high IMR, and details of govt schemes and expenditure aimed at tackling the crisis. On a question regarding what was the expenditure incurred in the previous fiscal year, the govt said it had spent Rs 110 crore under different schemes and activities to reduce the infant mortality rate. The primary causes of infant deaths in MP include premature birth, pneumonia, sepsis, low birth weight, birth asphyxia and diarrhea among other reasons, the minister said in his reply. The govt also listed the schemes, activities and budget allocation aimed to reduce infant mortality rate. It includes Anaemia Mukt Bharat, nutritional rehabilitation centre, total facility based newborn care, total child death review, total paediatric care, total Janani Shishu Suraksha Karyakram among several others.
The Hindu
4 days ago
- The Hindu
How far have we come in providing personalised radiation treatment for cancer patients?
Radiotherapy, also known as radiation oncology or radiation therapy, is an important arm of cancer therapy. It involves the use of high-energy ionizing radiation to predominantly treat malignancies, as well as certain benign conditions. In India, due to lack of awareness and inadequate cancer screening initiatives, a majority of cancer patients seek medical help when the disease is locally advanced, and hence are candidates requiring multi-modality treatment including various combinations of surgery, radiotherapy, chemotherapy, biological therapy and immunotherapy. Nearly 70% of cancer patients need radiotherapy as a part of their cancer treatment protocol, where its role may be a primary curative treatment, additional or adjunct treatment or palliative therapy to relieve symptoms in advanced disease stages. Also Read: ICMR study finds only 28.5% of cancer patients receive radiotherapy in India Understanding radiotherapy There are 2 primary treatment modalities in radiotherapy: teletherapy or external beam radiotherapy and brachytherapy. In the former, the patient is placed at a distance from the radiation-generating equipment (generating high-energy x rays or gamma radiation) and by virtue of the beam divergence, a homogenous dose is delivered to the tumour tissue. In brachytherapy, radiation-emitting radioactive sources are directly placed in contact with the tumour tissue and subsequently removed after a specific period of time, thereby delivering a high dose to the tumour directly. The last two decades have seen significant strides in the field of radiation oncology. Technological developments in hardware and software industries have led to development of equipment enabling high precision radiation delivery with sub-millimetre accuracy, resulting in better tumour control and reduction in treatment-related side effects arising out of damage to normal tissues adjacent to the tumour. Until a few years ago, access to this high precision radiotherapy treatment was restricted to large metropolitan cities. With the active involvement of government health agencies (both at the Centre and State levels) along with public private partnerships, there is currently a focussed attempt to reduce this disparity and improve the availability of radiotherapy treatment at most district-level hospitals. Contemporary radiotherapy treatment Contemporary high precision radiotherapy treatment techniques such as Intensity modulated radiotherapy (IMRT), Image Guided Radiotherapy (IGRT), Volumated Arc therapy (VMAT/Rapid Arc), Stereotactic Radiosurgery and Stereotactic Radiotherapy (SRS and SRT), have enabled treatment of cancer tissues with higher radiation doses and with preferential sparing of normal tissue. These techniques have also enabled the feasibility of organ preservation in daily practice. In spite of these benefits, all cancer patients undergoing radiotherapy do not get cured of cancer. An important limitation of present-day cancer treatment, including radiation therapy, is that the response of a tumour to treatment varies from person to person ranging from complete response to partial response and in some cases, disease progression despite treatment. This is due to differences in the genetic and protein composition of the tumours which varies from patient to patient and which can influence treatment outcomes. Another important limitation is treatment-related side effects, which vary from patient to patient and can interfere with treatment compliance necessitating lifestyle modifications during, and post treatment. In simple terms 'one size does not fit all'. Although the prescribed radiotherapy treatment might be the global established standard of care for a particular disease condition and stage, individual variations in treatment response and tolerance are the norm, which cannot currently be predicted based on any assessment tool. While available radiotherapy guidelines are mainly based on the average response of disease population to treatment, this approach fails to account for individual tumour variations with respect to their molecular and genetic signature as well as patient heterogeneity with respect to their demography, genetic makeup and pattern of lifestyle. There is an unmet need to develop markers which can predict or identify non-responders to radiation and those patients who are likely to develop disease progression while on treatment. There is also an urgent need to identify patients who are likely to suffer significant toxicity and discontinue treatment. In this regard, there exists an unmet need to develop drugs which can reduce radiation- related toxicity without interfering with the radiation's anti-tumour capabilities. Can newer tech such as proton therapy solve the problem? The introduction of proton therapy in India along with its dosimetric capability of delivering radiation doses only at a particular range of depth within the patient's body, has significantly reduced early and late complications of radiotherapy with the latter being an important advantage in treatment of paediatric patients. But proton therapy is not a personalised radiotherapy solution and patients can still have residual disease or recurrent disease after proton therapy, based on the radiosensitivity of the tumour. Also, the limited availability of proton therapy presently in India and the high cost of treatment are other inherent issues that render it as a non-viable treatment solution for a majority of Indian patients who cannot afford the cost. Thus there is an inherent need for developing personalised radiotherapy treatment practises which can allow a physician to predict the possible treatment response and risk of recurrence of a particular disease based on its molecular and genetic composition. Such a personalised radiotherapy protocol would have the following advantages in that it can: Provide optimal radiation treatment tailored to each patient tumour's unique biological and clinical characteristics Predict tumour response to radiotherapy prior to initiation of treatment thereby avoiding treatment- related toxicity in potential non-responders Then the pertinent question which arises is whether such a personalised radiotherapy protocol or assessment tool is in existence or whether it can be developed? The answer is a resounding yes. The promise of research into genetics and AI In recent years, probing research in the field of molecular oncology, genetics and artificial intelligence (AI) are bringing the concept of personalized radiotherapy closer to actual realization. At one end, data-driven AI and deep learning models are being developed to identify predictors of radiation sensitivity. This information is being gathered by accessing huge quantities of data regarding tumour behaviour and their associated pathological and molecular characteristics collected over the years, and corelating them with the outcomes of radiotherapy treatment already delivered. The following areas of medical research are contributing in a big way to the development of personalised radiotherapy treatment in the near future. These include – Digital pathology – This involves acquisition and interpretation of pathology information in digital format and environment. This, in turn, improves rapid referral of cases between hospitals and doctors for expert opinions or second opinions and facilitates incorporation of digital training resources into pathology reporting, paving the way for integration of AI in pathological reporting. Radiomics in prognostication – This involves analysis of certain patterns and disease characteristics from radiological scans, and the use of this information to predict patient outcomes and treatment responses to cancer. Radiomics aims to provide more precise information to guide treatment decisions. Genomics and proteomics-based treatment decisions – The development of bioinformatics and its integration with tumour-related genetics and molecular information is being used to develop genomic and proteomic-based tumour biology panels, which can help in early diagnosis as well as predict response to treatment. This can lead to more personalised and effective cancer treatment strategies. AI-based adaptive radiotherapy – A revolutionary concept in radiotherapy, this involves the use of AI-based tools to analyse tumour-related changes during a course of radiotherapy. In adaptive RT, before a patient receives his scheduled daily radiotherapy treatment, he is subjected to a CT scan or MR images which are acquired on the radiotherapy machine, prior to treatment. These images acquired are interpreted by AI-based programmes, which then calculate changes in tumour geometry based on daily radiation response. The radiation plan is then altered real time, and adjusted on a daily basis to effectively target the tumour and reduce damage to healthy tissues. This approach enhances the therapeutic ratio of the treatment, potentially improving cure rates while minimising side effects. One other area of research which is going to influence personalised radiotherapy services positively, is work on nanoparticle technology, which can enable a higher concentration of drugs delivered directly inside the tumour or its related microenvironment thereby increasing radiotherapy associated tumour damage and minimising normal tissue damage. AI-driven assessment of oral and gastrointestinal microbiome changes in response to radiotherapy are also being assessed as a prognostic tool to predict radiation responses. Another important development is research aimed at integrating daily PET CT scans into adaptive radiotherapy (biological adaptive RT), which adds functional information of the treatment along with anatomical data to refine adaptive radiotherapy plans. Although a lot of research efforts are currently underway in multi-directional fields with a single-minded focus on enabling personalised cancer treatment strategies, a lot of validation needs to be further done in this regard to enable these modalities to be incorporated into daily treatment protocols. However, the good news is that we have indeed covered a lot of ground in realising this dream and the day is not far when the concept of personalised radiotherapy will be translated from the laboratory bench to bedside practise. (Dr. K. Satish Srinivas is professor and head of the department of radiation oncology, SRIHER, Chennai.
